Ionis PharmaceuticalsIONS
Recorded

Ionis Pharmaceuticals UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

All right, we'll get started. Thank you for joining us this morning for inaugural UBS Global Biopharma Conference. For this session, we have Dr. Brett Monia, CEO of Ionis. Brett, thanks for joining us for this fireside chat. For the audience who may be new to the story, could you just spend a few minutes describing who Ionis is, your recent accomplishments, and why investors should pay attention to Ionis now?

Brett MoniaCEO

Sure. Thanks, Jun. It's great to be here. So, yeah, so for those that aren't that familiar with Ionis is a pioneer in oligonucleotide therapeutics targeting RNA. You may be familiar with antisense technology, siRNA technology. That's really where we're focused, and we're the leaders in this space. Today, we have seven FDA-approved medicines for eight disease indications. That's the most of any oligonucleotide company that's out there today. About half of those approved medicines we're commercializing ourselves in the U.S., and then the other half, we have pharma partners that are commercializing or developing. In addition, we have a very rich phase III late-stage pipeline at Ionis. Just recently, in the last few months, we announced positive phase III data for two programs, one in kidney disease and another in a genetic form of ALS.

Brett MoniaCEO

We have four phase III programs in development today, and more expecting next year. Some are wholly owned, as well as some are our partner. We have a rich mid-stage pipeline. Basically, we have a technology, a platform, and a pipeline that's positioned to deliver a steady cadence of breakthrough treatments for common diseases as well as rare genetic diseases we've already done, as well as in the near future, as well as in a long-term basis. Ionis is very well-positioned to continue to deliver breakthrough medicines for many years to come.

Operator

Thank you for that. Let's start with your lead drug, the most important drug at the moment, TRYNGOLZA, recently approved for severe hypertriglyceridemia. It's a large opportunity. The launch has been slower than expected, as you admitted on the call. What gives you confidence that TRYNGOLZA can actually achieve $3 billion plus in sales, and how do you get there?

Brett MoniaCEO

TRYNGOLZA is a breakthrough for a condition called severe hypertriglyceridemia. This is a lipid. Triglycerides are a lipid in this population in which triglycerides are 10, 20, sometimes 50 times higher than normal levels of triglycerides. These patients suffer from a whole range of comorbidities, but most importantly, the risk of a potentially fatal acute pancreatitis attack of the pancreas. If it's not fatal, it's highly debilitating and is recurring, so eventually it can lead to pancreatic failure and organ failure and so on. Prior to TRYNGOLZA, there have been no effective treatments for severe hypertriglyceridemia. What we showed in our phase III trial was that not only can we normalize many patients' triglycerides who have severe hypertriglyceridemia, but we can actually reduce the incidence of acute pancreatitis attacks, so outcome data, if you will. That's never been shown before.

Brett MoniaCEO

We were first to do it, and we're the only FDA-approved medicine that can do this. We're talking millions of people in the U.S. alone, equal in Europe, that have severe hypertriglyceridemia. About 1 million of those several million are what we consider to be high risk. They've already had acute pancreatitis attacks, or their triglycerides are so high that they're going to have one eventually, probably. TRYNGOLZA is positioned to be able to deliver. That is a big part of the confidence, is the incredible profile that we delivered in our phase III trial, reductions in acute pancreatitis and triglycerides, while good safety, tolerability, and the convenience of once-per-month self-administration using an auto-injector. A compelling profile and the very, very high unmet medical need. You mentioned that the launch is off to a slower start than expected.

Brett MoniaCEO

Let's keep in mind that we're only three months into a launch in which we're creating a brand new category, like a brand new therapeutic area where HCPs need to get familiar with the first time a treatment's available to treat this disease, this condition that they've been managing for a long time. They have to get familiar with the process. They have to get familiar with a very novel mechanism of action. There are conditions that are required to prescribe TRYNGOLZA. You have to get a triglyceride measurement and prove that you have severe hypertriglyceridemia. You have to have at least tried another triglyceride-lowering drug, a generic drug, like a fibrate or so on, and they have to get familiar with the office process and that kind of thing.

Brett MoniaCEO

We remain confident, despite a slightly slower ramp than what we originally expected in the multi-billion dollar product opportunity that TRYNGOLZA offers.

Operator

This acute pancreatitis, people sometimes view severe hypertriglyceridemia as yet another lipid disorder, but it causes AP. Can you contextualize that for the investors, the severity of that, and what could happen if you have that?

Brett MoniaCEO

It can be fatal, and oftentimes is fatal. It is the number one cause of acute pancreatitis fatality of any cause. You can get acute pancreatitis from alcoholism or from other conditions, diabetes, but the number one cause of fatality due to acute pancreatitis is severely elevated triglycerides. If it is not fatal, almost all the time it lands an individual in an ICU, an intensive care unit, in which they have to stay in an intensive care unit up to a week or two before they can get out of that unit and then go on. Then they are at risk for another attack down the road if they cannot get their triglycerides down. The other thing about acute pancreatitis is that there is almost nothing that a physician can do when they are in the ICU, right?

Brett MoniaCEO

They feed them intravenous fluids and they give them pain medications, but there is nothing that they can do to prevent the acute pancreatitis, to reverse that condition. So, the unmet need is very high. It is a severe outcome. Before TRYNGOLZA, there really have been no prophylactic approaches that can prevent that from happening.

Operator

What is it that the prescribers are waiting for? What are they looking for? Given this, and every KOL we spoke with, the data looks really great. You reduce acute pancreatitis risk by 80%, 90%.

Operator

Right ish. What exactly are they waiting for?

Brett MoniaCEO

Few things. One is familiarity. Familiarity with a brand new medicine, a new class of medicine, a new mechanism of action. We were the first to validate this mechanism of action for triglyceride lowering, targeting a lipoprotein that is called apoC-III. They want to get familiar with that, they want to get familiar with the medicine, they want to get familiar with the process that qualifies a patient. As I mentioned before, a generic triglyceride-lowering drug will have to fail. Most of these patients, many of these patients are on those drug treatments already anyway. They have to get a measure, a triglyceride measure. They want to make sure the office process is not too cumbersome. We target cardiologists, endocrinologists, lipid specialists.

Brett MoniaCEO

A lot of cardiologists have had bad experiences with other meds that have caused processes in their offices to really get backed up because the access has been very difficult. We are streamlining that, but they want to get familiar with that. They also want to see that sometimes the clinical outcome. One of the things that we are seeing is a lot of enthusiasm, HCP to prescribe TRYNGOLZA.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day